These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33721598)

  • 21. Pitolisant to Treat Excessive Daytime Sleepiness and Cataplexy in Adults with Narcolepsy: Rationale and Clinical Utility.
    Guevarra JT; Hiensch R; Varga AW; Rapoport DM
    Nat Sci Sleep; 2020; 12():709-719. PubMed ID: 33117007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. pitolisant, a novel histamine-3 receptor competitive antagonist, and inverse agonist, in the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
    Sarfraz N; Okuampa D; Hansen H; Alvarez M; Cornett EM; Kakazu J; Kaye AM; Kaye AD
    Health Psychol Res; 2022; 10(3):34222. PubMed ID: 35774905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of modafinil and pitolisant in narcolepsy: a non-inferiority meta-analytical approach.
    Lehert P; Szoeke C
    Drugs Context; 2020; 9():. PubMed ID: 32699548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy.
    Bogan RK; Feldman N; Emsellem HA; Rosenberg R; Lu Y; Bream G; Khayrallah M; Lankford DA
    Sleep Med; 2015 Sep; 16(9):1102-8. PubMed ID: 26298786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pitolisant for Residual Excessive Daytime Sleepiness in OSA Patients Adhering to CPAP: A Randomized Trial.
    Pépin JL; Georgiev O; Tiholov R; Attali V; Verbraecken J; Buyse B; Partinen M; Fietze I; Belev G; Dokic D; Tamisier R; Lévy P; Lecomte I; Lecomte JM; Schwartz JC; Dauvilliers Y;
    Chest; 2021 Apr; 159(4):1598-1609. PubMed ID: 33121980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Oral JZP-110 (ADX-N05) on Wakefulness and Sleepiness in Adults with Narcolepsy: A Phase 2b Study.
    Ruoff C; Swick TJ; Doekel R; Emsellem HA; Feldman NT; Rosenberg R; Bream G; Khayrallah MA; Lu Y; Black J
    Sleep; 2016 Jul; 39(7):1379-87. PubMed ID: 27166238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy.
    Romigi A; Vitrani G; Lo Giudice T; Centonze D; Franco V
    Drug Des Devel Ther; 2018; 12():2665-2675. PubMed ID: 30214155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple treatment comparison in narcolepsy: a network meta-analysis.
    Lehert P; Falissard B
    Sleep; 2018 Dec; 41(12):. PubMed ID: 30239930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pitolisant: First Global Approval.
    Syed YY
    Drugs; 2016 Sep; 76(13):1313-1318. PubMed ID: 27438291
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy.
    Kushida CA; Shapiro CM; Roth T; Thorpy MJ; Corser BC; Ajayi AO; Rosenberg R; Roy A; Seiden D; Dubow J; Dauvilliers Y
    Sleep; 2022 Jun; 45(6):. PubMed ID: 34358324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Criteria for gauging response to sodium oxybate for narcolepsy.
    Steffen AD; Lai C; Weaver TE
    J Sleep Res; 2018 Aug; 27(4):e12628. PubMed ID: 29205601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial.
    Dauvilliers Y; Verbraecken J; Partinen M; Hedner J; Saaresranta T; Georgiev O; Tiholov R; Lecomte I; Tamisier R; Lévy P; Scart-Gres C; Lecomte JM; Schwartz JC; Pépin JL;
    Am J Respir Crit Care Med; 2020 May; 201(9):1135-1145. PubMed ID: 31917607
    [No Abstract]   [Full Text] [Related]  

  • 33. [Pitolisant for the treatment of narcolepsy with or without cataplexy].
    Bruhn C
    Med Monatsschr Pharm; 2016 Aug; 39(8):324-9. PubMed ID: 29984945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): a systematic review and meta-analysis of randomized controlled trials.
    Boscolo-Berto R; Viel G; Montagnese S; Raduazzo DI; Ferrara SD; Dauvilliers Y
    Sleep Med Rev; 2012 Oct; 16(5):431-43. PubMed ID: 22055895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Real-life WAKE study in narcolepsy patients with cataplexy treated with pitolisant and unresponsive to previous treatments].
    Del Río-Villegas R; Martínez-Orozco FJ; Romero-Santo Tomás O; Yébenes-Cortés M; Gómez-Barrera M; Gaig-Ventura C
    Rev Neurol; 2022 Oct; 75(7):165-171. PubMed ID: 36169322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pitolisant: Pediatric First Approval.
    Keam SJ
    Paediatr Drugs; 2023 Jul; 25(4):483-488. PubMed ID: 37233887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy.
    Bogan RK; Thorpy MJ; Dauvilliers Y; Partinen M; Del Rio Villegas R; Foldvary-Schaefer N; Skowronski R; Tang L; Skobieranda F; Šonka K
    Sleep; 2021 Mar; 44(3):. PubMed ID: 33184650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications.
    Thorpy MJ; Bogan RK
    Sleep Med; 2020 Apr; 68():97-109. PubMed ID: 32032921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized study of solriamfetol for excessive sleepiness in narcolepsy.
    Thorpy MJ; Shapiro C; Mayer G; Corser BC; Emsellem H; Plazzi G; Chen D; Carter LP; Wang H; Lu Y; Black J; Dauvilliers Y
    Ann Neurol; 2019 Mar; 85(3):359-370. PubMed ID: 30694576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation.
    Plazzi G; Ruoff C; Lecendreux M; Dauvilliers Y; Rosen CL; Black J; Parvataneni R; Guinta D; Wang YG; Mignot E
    Lancet Child Adolesc Health; 2018 Jul; 2(7):483-494. PubMed ID: 30169321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.